SPR-720 DNA gyrase subunit B (GyrB) (bacterial) inhibitor Treatment of nontuberculous mycobacterial-pulmonary diseases

SPR-720 is a once-daily, orally bioavailable prodrug of SPR-719 (VXc-486), a broad-spectrum aminobenzimidazole inhibitor of ATPase activity of gyrase B/ParE. SPR-720 is being -developed by Spero Therapeutics to treat infections caused by nontuberculous mycobacteria (NTM). In preliminary studies, SPR-720 has been shown to inhibit both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis, multiple isolates of Mycobacterium abscessus, Mycobacterium avium complex and Mycobacterium kansasii with MICs ranging from 0.1 to 2 mu g/mL. SPR-720 is a broad-spectrum oral candidate that, if approved, may be used to treat both nonrefractory and refractory mycobacterial infections. The U.S. Food and Drug Administration has designated SPR-720 as a qualified infectious disease product (QIDP) for the treatment of lung-infections caused by NTM and M. tuberculosis, and has granted orphan drug and fast track status for the treatment of NTM infection.